Contineum Therapeutics, Inc. (CTNM)
$17.05-$0.20 (-1.16%) Today
Tim Watkins - OfficerContineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 64,052 | $1.02M |
| Grant or award | 7 | 133,000 | |
| Option exercise | 18 | 119,764 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
31 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 6,091 | $16.37 | $100K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 99 | $17.05 | $2K |
This is as far as the anonymous view goes. Create a free account for all 31 CTNM filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Daniel Lorrain | Officer | 9,520 | $147K | View on EDGAR | |
| CARMINE STENGONE | Director | 2,500 | $39K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Contineum Therapeutics, Inc. (CTNM) had 13 insider filings in the last 90 days, with the most recent on 2026-08-03. The full record for CTNM runs to 31 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CTNM were filed in the last 90 days.
9 insider sales of CTNM were filed in the last 90 days, totaling $1.02M.
This page tracks CTNM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CTNM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
